Neuland Laboratories Ltd Q3 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/4gc3i224zepnggm0z2hdpmuy.pdf

Key Takeaways


Peptide Investment & Strategy

Davuluri: "At the moment, we don't have any definitive visibility on revenues or products or cash flow. So, we will have to see how it goes. It will probably take 3 to 5 years to ramp up this investment."

Segment Performance & Mix


Revenue Volatility & Classification

Davuluri: "I would not look at the quarter-to-quarter movement to look and maybe call it a decline or a growth, because I think a lot of times these products are lined up to get dispatched across different quarters in a year."

Pipeline & Growth Visibility


Margins & Cost Structure


Tariff Risk & Competitive Position

Davuluri: "It seems very unlikely that tariffs could be affecting our business directly... for most of the products we operate on both in the GDS and CMS side, we are typically one of the only suppliers or maybe one of the two suppliers and a supplier risk would actually harm US patients."

Guidance & Commitments

CommitmentSpecificsTimeline
FY25 revenueClose at a relatively flat levelFY25 end
Growth resumptionGrowth expected to resumeFY26 onward
New production block (Unit III)Commercial production to commenceFY26
Pre-commercial molecule commercializationAt least one, possibly two, of 11 pre-commercial molecules to go commercialFY26 or FY27; one fairly certain in the next year
Peptide capacity investment₹254 crores across large-scale manufacturing, pilot, and R&DInvestment announced; ramp over 3–5 years

Key Metrics

MetricQ3 FY25
Total income₹401.9 cr, +1.8% YoY
Gross margin53.2%, vs 59.8% in Q3 FY24
EBITDA (excluding exceptional items)₹90.3 cr, margin 22.5%
Profit after tax₹101.4 cr, vs ₹80.7 cr in Q3 FY24; includes exceptional gain of ₹55.8 cr from sale of investment property
EPS₹79 per share
9M FY25 revenue₹1,161.5 cr, marginal degrowth of 1.7% YoY
9M FY25 EBITDA (excluding exceptional items)₹284.6 cr, vs ₹362 cr in 9M FY24
9M FY25 free cash flow₹70.8 cr
Net debtNegative ₹185.1 cr (net cash position)
Working capital111 days of sales
FY25 revenue outlookRelatively flat, in line with prior commentary
FY26 growth outlookGrowth expected to resume
CMS active projects97, of which 19 are commercial
CMS development revenue (9M FY25)₹116 cr, vs ₹222 cr in 9M FY24
Peptide capacity investment approved₹254 cr, for large-scale, pilot, and R&D facilities
S&P ESG rating70, up from 64